The expanded indication allows the viscoelastic testing system to assess coagulation in trauma patients, adding to its existing uses in cardiovascular surgery and liver transplantation.


Werfen has received US Food and Drug Administration (FDA) 510(k) clearance for its ROTEM sigma complete cartridge to assess peri-operative hemorrhage and/or thrombosis in trauma. The company announced the clearance today.

The new indication extends the ROTEM sigma viscoelastic testing system beyond cardiovascular surgery and liver transplantation. It allows laboratories and hospitals in the US to use the system for bleeding management in trauma.

Traumatic injury accounts for roughly 10% of deaths worldwide, and uncontrolled bleeding remains a leading cause of potentially preventable death after severe trauma, according to Werfen. Trauma-induced coagulopathy adds to the challenge because it requires fast assessment and timely intervention. Current trauma management guidelines recommend viscoelastic testing as part of a goal-directed approach to bleeding management and coagulation support, the company says.

“Trauma teams are required to make critical treatment decisions within minutes, when every moment matters,” says Bill Crandell, vice president, commercial operations, North America at Werfen, in a release. “The clearance of the ROTEM sigma complete cartridge for use in trauma expands access to rapid, actionable coagulation information at the point of care, helping make informed treatment decisions during trauma resuscitation.”

How the System Works

ROTEM sigma is a fully automated system that assesses clot initiation, clot firmness, and clot stability in real time at the point of care. Werfen says the information supports individualized treatment strategies during critical bleeding events.

The system uses a cartridge-based design with closed-tube direct sampling, which is intended to limit manual handling steps and reduce operator-dependent variability. Other features include automated assay initiation, integrated quality control, continuous internal system monitoring, a touchscreen interface, and room-temperature cartridge storage. Werfen says the reduced operator interaction is designed to simplify implementation across a variety of acute care settings.

Clinicians can view TEMograms, the graphical output of clot dynamics, on the instrument. They can also use GEMweb Live to see coagulation data in real time.

The ROTEM sigma complete cartridge includes four assays: INTEM C, EXTEM C, FIBTEM C, and APTEM C. A separate cartridge, ROTEM sigma complete + hep, includes INTEM C, EXTEM C, FIBTEM C, and HEPTEM C. It remains indicated for cardiovascular surgery and liver transplantation.

The ROTEM sigma system analyzes 3.2% citrated venous or arterial whole blood samples. It is indicated for adults 21 years and older when a semiquantitative evaluation of blood coagulation properties is desired, in point-of-care and laboratory settings. It is not intended for use in pre-hospital trauma settings.

Werfen notes that ROTEM sigma results should not be the sole basis for a diagnosis. They should be considered alongside the patient’s clinical condition and other laboratory tests.

Photo caption: ROTEM sigma complete cartridge to assess peri-operative hemorrhage and/or thrombosis in trauma.

Photo credit: Werfern